Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026

Illumina reported Q3 2026 revenue of $1.13B, up 4.2% YoY. GAAP EPS was $1.43. The company raised full-year revenue guidance to $4.64B-$4.66B and EPS guidance to $5.40-$5.45, citing strong clinical demand and NovaSeq X placements. Cash flow from operations was $419M, with free cash flow at $378M.

Original reporting
Published Oct 29, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026 — source image
Decision brief

The 30-second read

$ILMNBullishHigh
01

Why it matters

The raised guidance signals stronger market demand and may trigger re‑rating by analysts.

02

Market read

Earnings beat and guidance lift are likely to move Illumina's stock and influence related biotech equities.

03

What to watch

Potential regulatory risk in China and tariff uncertainties could temper upside.

Relevance 8/10Novelty 8/10Timing: pre‑market tomorrow

Background

Illumina is a leading provider of DNA sequencing systems; its results are closely watched for biotech sector health.

Company-level read

Ticker impact

$ILMNBullishHigh confidence
Context

Illumina released Q3 FY2026 results and raised full‑year revenue and EPS guidance.

Expected impact

likely upward pressure as investors price in higher revenue and earnings outlook

Evidence & confidence

Revenue guidance increased to $4.64‑$4.66B and EPS to $5.40‑$5.45, both above prior guidance, indicating improved performance.

Market effects

May lift other genomics and biotech stocks as the sector benefits from higher demand for sequencing.

Positive for US biotech listings; limited direct effect elsewhere.

Reinforces optimism for global life‑science investors tracking Illumina's AI‑driven platform.

Counterpoint

If the guidance raise is already priced in, any short‑term pull‑back could present a buying opportunity.

Key entities

  • Jacob Thaysen

    CEO of Illumina, quoted on results and outlook.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.